GPBAR1 and metabolic dysfunction-associated steatohepatitis: Therefore, in the window of metabolic disorders, the development of ligands covering steroidal and non-steroidal chemical space endowed with dual activity toward GPBAR1 and FXR appears to be a promising strategy in non-alcoholic steatohepatitis (NASH), hypercholesterolemia, hypertriglyceridemia, and T2DM [17,18,19,20].